Discovery of Rimonabant and its potential analogues as anti-TB drug candidates

Rimonabant and its analogues have been synthesized in moderate to good yields using a simple synthetic route. All the newly synthesized compounds were subjected to in vitro screening against M. tuberculosis and M. smegmatis . The most potent analogue JMG-14 exhibits MIC value of 3.13 compared to 3.2...

Full description

Saved in:
Bibliographic Details
Published inMedicinal chemistry research Vol. 24; no. 7; pp. 2960 - 2971
Main Authors Gajbhiye, J. M., More, N. A., Patil, Manoj D., Ummanni, R., Kotapalli, S. S., Yogeeswari, P., Sriram, D., Masand, V. H.
Format Journal Article
LanguageEnglish
Published New York Springer US 01.07.2015
Subjects
Biochemistry
Biomedical and Life Sciences
Biomedicine
Cell Biology
Original Research
Pharmacology/Toxicology
Diaryl pyrazoles
Tuberculosis
MTCYP-121
Rimonabant
Mycobacterium tuberculosis
H37Rv
Online AccessGet full text

Cover

More Information
Summary:Rimonabant and its analogues have been synthesized in moderate to good yields using a simple synthetic route. All the newly synthesized compounds were subjected to in vitro screening against M. tuberculosis and M. smegmatis . The most potent analogue JMG-14 exhibits MIC value of 3.13 compared to 3.25 and 50 µg/ml for ethambutol and pyrazinamide, respectively. The molecular docking reveals that pyrazole ring, number and position of halogen atoms play a crucial role in deciding interactions with MTCYP-121. These findings open up a new avenue in the search of potent anti-TB drugs with rimonabant and its novel analogue JMG-14 as lead molecules. Graphical Abstract
ISSN:1054-2523
1554-8120
DOI:10.1007/s00044-015-1346-4